Diagnostics
Todos Medical Ltd. announced it has entered into a binding term sheet with HWH World Pte Ltd., a wholly-owned subsidiary of Singapore eDevelopment for the grant of exclusive marketing rights for Todos Medical’s TM-B1 and TM-B2 tests to HWH World’s network of members in Singapore, Malaysia, the Philippines, Vietnam, Thailand, Indonesia, South Korea, Hong Kong, China, the United States and Canada.
The receptivadx can have meaningful impact on women struggling with unexplained infertility by giving them an answer to their infertility. Learn more here.
Clinical Utility Study will Evaluate the Prolaris® Test in Men with Prostate Cancer
Selux Diagnostics, Inc. announced its selection to present a poster and participate in a panel discussion at IDWeek 2019 – the upcoming Infectious Diseases Society of America conference.
QuantuMDx Group appoints Neil Butler as a Non-Executive Director
Oncimmune Holdings plc welcomes the presentation of data by Professor Frank Sullivan (Chief Investigator on the ECLS trial) which has demonstrated the potential of Oncimmune’s EarlyCDT® Lung test to reduce the incidence of patients with late-stage lung cancer at diagnosis, compared with standard clinical diagnosis.
65 Percent of Patients Remained on Active Surveillance for More than Four Years
Todos Medical Ltd. announced that the Company has entered into a non-binding Memorandum of Understanding with Orot+, the operational division of Orot-Luces, to expand their existing launch and distribution partnership for the commercial sale of Todos’ early breast cancer detection blood tests TM-B1 and TM-B2 into Japan.
In China, much like the United States, it is incredibly difficult to obtain a patent for a diagnostic method.
Biopharma companies are working with diagnostic companies to develop companion diagnostic tests to go along with specific therapies, often cancer drugs.
PRESS RELEASES
